Current Progress in the Understanding of Secondary Brain Damage from Trauma and Ischemia: Proceedings of the 6th International Symposium: Mechanisms . 1998 (Acta Neurochirurgica Supplement, 73)

Baethmann A. Eriskat J. Plesnila N. Ringel F.

ISBN 10: 3211833137 / ISBN 13: 9783211833131

Published by Springer, 1999

About this Item

pp. viii + 120.

Seller Inventory # 1814418134

Bibliographic Details

• Title: Current Progress in the Understanding of Secondary Brain Damage from Trauma and Ischemia: Proceedings of the 6th International Symposium: Mechanisms . 1998 (Acta Neurochirurgica Supplement, 73)
• Publisher: Springer
• Publication Date: 1999
• Language: English
• ISBN 10: 3211833137
• ISBN 13: 9783211833131
• Binding: Hardcover
• Condition: New

About this title

Synopsis

Information is provided from the basic and clinical sciences on the mechanisms damaging the brain from trauma or ischemia. New aspects involve the endoplasmic reticulum, mitochondrial failure, pathobiology of axonal injury, molecular signals activating glial elements, or the emerging therapeutical role of neurotrophins. Experimental issues involve a better analysis of the ischemic penumbra, the salvagable tissue. Therapeutic contributions reach from the environmental influence to gene expression, including neuroprotection, such as hibernation – mother nature’s experiment – or hypothermia which is reported to induce cell swelling. Treatment issues deal also with thrombolysis and combination therapies, or with the clearance of adverse blood components – LDL/fibrinogen – by a novel procedure using heparin. Other highlights are discussing the specificities of pediatric vs. adult brain trauma, or the evolving role of the Apolipoprotein-E e4 gene in severe head injury. An update is also provided on an online assessment of the patient management during the pre- and early hospital phase in Southern Bavaria. The empirical observation of neuroworsening is analyzed in further details, whether this is a specificity autonomously driving the posttraumatic course. Finally, the unsolved question why drug trials in severe head injury have failed so far in view of the promising evidence from the laboratory is subjected to an expert analysis.